Compare Ginkgo Bioworks Holdings Inc (DNA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Health Care Select Sector SPDR Fund — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M), while Health Care Select Sector SPDR Fund trades at $158.85. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | XLV | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | — |
52-Week High | $16.14 | $164.48 |
52-Week Low | $5.48 | $129.01 |
Enterprise Value | $627.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
XLV trades at $161.41, up 0.35% with a bullish technical signal from moving averages. The healthcare ETF benefits from State Street's upgraded sector outlook and strong performance from holdings like Johnson & Johnson. Technical indicators show the price near pivot point resistance at $162 with ADX signaling strong trend momentum.
Healthcare sector rotation provides tailwinds as investors seek defensive exposure amid tech volatility. Key risks include patent cliffs and regulatory uncertainty, but diversified healthcare exposure offers stability with upcoming dividend distribution in June 2026 supporting total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
